Observational studyEuropean journal of clinical pharmacology2026
Maternal and neonatal outcomes of antithrombotic therapy in pregnant women with valvular or complex congenital heart disease: a nationwide retrospective cohort study in Japan.
Observational study in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeCertain women with heart disease require lifelong antithrombotic therapy. However, the impact of such therapy during pregnancy on maternal and neonatal outcomes remains unclear. This study aimed to investigate the prescription patterns and clinical outcomes associated with antithrombotic therapy in pregnant women with heart disease.
methodsUsing a Japanese administrative claims database, we identified pregnant women diagnosed with valvular heart disease or complex congenital heart disease between January 2008 and July 2023. In this retrospective observational study, we compared maternal clinical outcomes between women who were prescribed antithrombotic drugs during pregnancy and those who were not. For infants who could be linked to their mothers in the database, neonatal outcomes were also assessed.
resultsA total of 550 pregnant women with a history of heart disease were identified, of whom 90 (16.4%) received antithrombotic therapy during pregnancy. Women who received antithrombotic therapy had a higher proportion of cesarean delivery (90.0% vs. 49.8%, p < 0.001). Intensive care unit (ICU) admission rate was significantly higher in this group (24.4% vs. 10.5%, p < 0.001), as was critical obstetric bleeding (13.3% vs. 1.7%, p = 0.009). No in-hospital maternal deaths or fatal arrhythmias were observed. Among the neonates associated with their mothers, a total of 238 were identified. Admission to a neonatal ICU was significantly more frequent among infants born to women who received antithrombotic therapy (35.7% vs. 13.3%, p = 0.001).
conclusionAlthough careful maternal and neonatal management is necessary, no in-hospital maternal deaths or severe cardiovascular events were observed among women prescribed antithrombotic therapy. This study provides valuable evidence to inform clinical decision-making in pregnant women with valvular heart disease requiring antithrombotic therapy in Japan.
Indexed as
Identifiers
42056467What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.